1. Home
  2. Discloses

Tags : Discloses

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)
Biosimilars

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

Tuba Khan September 1, 2020

Shots: The company discloses two additional biosimilars in active development referencing Opdivo (nivolumab) and Keytruda (pembrolizumab). The biosimilars are in the advanced stages of pre-clinical development and are being co-developed by NeuClone and Serum Institute of India The disclosure demonstrates NeuClone’s ability to develop multiple biosimilars simultaneously through its NeuMAX platform Additionally, NeuClone and Serum […]Read More

Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize Novartis’ Products for $463M
Pharma

Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize

Vartika Singh September 7, 2018

Shots:  Mylan reveals its undisclosed agreement signed on 30 July, 2018 for worldwide commercialization rights for Novartis’ global cystic fibrosis products,TOBI Podhaler and TOBI solution  Company also revealed the reason for keeping the deal undisclosed, as the transaction was under pre-closing confidentiality restrictions The focus of the purchase is to enrich its respiratory units in […]Read More

Copyright ©2021 PharmaShots | Powered by Octavus Consulting